Directa Plus (DCTA) 주식 개요Directa Plus Plc는 이탈리아, 루마니아 및 전 세계에서 산업 및 상업용 그래핀 기반 제품을 제조 및 판매하는 회사입니다. 자세히 보기DCTA 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6위험 분석의미 있는 시가총액이 없습니다(£7M)지난 5년간 매년 수익이 4.1% 감소했습니다.지난 3개월 동안 주가 변동성이 UK 시장과 비교했을 때 매우 높았습니다.최신 재무 보고서가 6개월 이상 지났습니다.모든 위험 점검 보기DCTA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.06733.0% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m10m2016201920222025202620282031Revenue €9.0mEarnings €847.9kAdvancedSet Fair ValueView all narrativesDirecta Plus Plc 경쟁사Symphony Environmental TechnologiesSymbol: AIM:SYMMarket cap: UK£17.7mHaydaleSymbol: AIM:HAYDMarket cap: UK£25.3mCarcloSymbol: LSE:CARMarket cap: UK£25.7mHardideSymbol: AIM:HDDMarket cap: UK£30.3m가격 이력 및 성과Directa Plus 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£0.06752주 최고가UK£0.2452주 최저가UK£0.05베타1.491개월 변동-0.74%3개월 변동-48.46%1년 변동-5.96%3년 변동-90.69%5년 변동-93.96%IPO 이후 변동-93.65%최근 뉴스 및 업데이트Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Nee Wharry Cope was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 29Directa Plus plc Announces Resignation of Wesley Clark as Director with Effective 27 April 2026Directa Plus Plc announced that Wesley Clark has resigned as director of the Company with effective 27 April 2026.New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.05m market cap, or US$9.49m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).공시 • Feb 28Directa Plus Plc announced that it expects to receive €4 million in fundingDirecta Plus Plc announced a private placement of non-dilutive potential loan for gross proceeds of €4 million from new lender Nant Capital, LLC on February 27, 2026.공시 • Feb 27+ 1 more updateDirecta Plus plc Announces Giorgio Bonfanti Steps Down from the Board, Effective At the End of MarchDirecta Plus Plc announced that Giorgio Bonfanti, the Company's Chief Financial Officer, has informed the Board of his intention to step down as a director of the Company, to pursue a new business opportunity, and will leave the Group at the end of March. The Board has commenced a recruitment process for a permanent replacement and in the meantime, a UK based finance professional with AIM experience will act as interim CFO.공시 • Jan 07Directa Plus plc Announces Changes to Its Board, Effective from January 31, 2026Directa Plus Plc announced that Richard Hickinbotham, Non-Executive Chairman, who would have shortly completed his nine-year tenure with the Group, has informed the Board of his intention to take up a full-time executive role and will step down from the Board on 31 January 2026. Giulio Cesareo will assume the role of Interim plc Chairman with effect from that date.더 많은 업데이트 보기Recent updatesBoard Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Nee Wharry Cope was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 29Directa Plus plc Announces Resignation of Wesley Clark as Director with Effective 27 April 2026Directa Plus Plc announced that Wesley Clark has resigned as director of the Company with effective 27 April 2026.New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.05m market cap, or US$9.49m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).공시 • Feb 28Directa Plus Plc announced that it expects to receive €4 million in fundingDirecta Plus Plc announced a private placement of non-dilutive potential loan for gross proceeds of €4 million from new lender Nant Capital, LLC on February 27, 2026.공시 • Feb 27+ 1 more updateDirecta Plus plc Announces Giorgio Bonfanti Steps Down from the Board, Effective At the End of MarchDirecta Plus Plc announced that Giorgio Bonfanti, the Company's Chief Financial Officer, has informed the Board of his intention to step down as a director of the Company, to pursue a new business opportunity, and will leave the Group at the end of March. The Board has commenced a recruitment process for a permanent replacement and in the meantime, a UK based finance professional with AIM experience will act as interim CFO.공시 • Jan 07Directa Plus plc Announces Changes to Its Board, Effective from January 31, 2026Directa Plus Plc announced that Richard Hickinbotham, Non-Executive Chairman, who would have shortly completed his nine-year tenure with the Group, has informed the Board of his intention to take up a full-time executive role and will step down from the Board on 31 January 2026. Giulio Cesareo will assume the role of Interim plc Chairman with effect from that date.New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£11.0m market cap, or US$14.8m).Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Non-Executive Director Nee Wharry Cope was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.분석 기사 • Oct 06Health Check: How Prudently Does Directa Plus (LON:DCTA) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 28First half 2025 earnings released: €0.016 loss per share (vs €0.037 loss in 1H 2024)First half 2025 results: €0.016 loss per share (improved from €0.037 loss in 1H 2024). Revenue: €3.90m (up 15% from 1H 2024). Net loss: €1.65m (loss narrowed 33% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.New Risk • Sep 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (UK£10.7m market cap, or US$14.4m).공시 • Aug 04Directa Plus Plc to Report First Half, 2025 Results on Sep 24, 2025Directa Plus Plc announced that they will report first half, 2025 results on Sep 24, 2025New Risk • Jun 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 4.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risk Market cap is less than US$100m (UK£12.5m market cap, or US$17.0m).분석 기사 • Jun 12Is Directa Plus (LON:DCTA) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • Jun 07Directa Plus Plc, Annual General Meeting, Jun 30, 2025Directa Plus Plc, Annual General Meeting, Jun 30, 2025. Location: 7th floor, 50 broadway, sw1h 0db, london United KingdomReported Earnings • Jun 03Full year 2024 earnings released: €0.06 loss per share (vs €0.058 loss in FY 2023)Full year 2024 results: €0.06 loss per share (further deteriorated from €0.058 loss in FY 2023). Revenue: €6.83m (down 35% from FY 2023). Net loss: €5.14m (loss widened 33% from FY 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.90m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).분석 기사 • Mar 27Investors Aren't Entirely Convinced By Directa Plus Plc's (LON:DCTA) RevenuesWith a median price-to-sales (or "P/S") ratio of close to 1.2x in the Chemicals industry in the United Kingdom, you...New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.74m market cap, or US$8.52m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.27m market cap, or US$7.80m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (7.2% average weekly change).New Risk • Dec 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.57m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (10% average weekly change).Major Estimate Revision • Oct 02Consensus revenue estimates decrease by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €17.3m to €7.30m. EPS estimate unchanged from -€0.026 per share at last update. Chemicals industry in the United Kingdom expected to see average net income growth of 44% next year. Consensus price target of UK£1.15 unchanged from last update. Share price fell 28% to UK£0.12 over the past week.Reported Earnings • Sep 27First half 2024 earnings released: €0.037 loss per share (vs €0.028 loss in 1H 2023)First half 2024 results: €0.037 loss per share (further deteriorated from €0.028 loss in 1H 2023). Revenue: €3.39m (down 26% from 1H 2023). Net loss: €2.47m (loss widened 34% from 1H 2023). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.분석 기사 • Sep 26Investors Give Directa Plus Plc (LON:DCTA) Shares A 39% HidingThe Directa Plus Plc ( LON:DCTA ) share price has fared very poorly over the last month, falling by a substantial 39...New Risk • Sep 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Market cap is less than US$100m (UK£11.7m market cap, or US$15.6m).공시 • Sep 13Directa Plus Plc to Report First Half, 2024 Results on Sep 25, 2024Directa Plus Plc announced that they will report first half, 2024 results on Sep 25, 2024New Risk • Jul 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£21.9m market cap, or US$28.1m).분석 기사 • Jun 28A Piece Of The Puzzle Missing From Directa Plus Plc's (LON:DCTA) Share PriceThere wouldn't be many who think Directa Plus Plc's ( LON:DCTA ) price-to-sales (or "P/S") ratio of 1.2x is worth a...Reported Earnings • Jun 27Full year 2023 earnings released: €0.06 loss per share (vs €0.073 loss in FY 2022)Full year 2023 results: €0.06 loss per share (improved from €0.073 loss in FY 2022). Revenue: €10.9m (flat on FY 2022). Net loss: €3.86m (loss narrowed 20% from FY 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Price Target Changed • Jun 13Price target decreased by 20% to UK£1.28Down from UK£1.59, the current price target is an average from 2 analysts. New target price is 589% above last closing price of UK£0.18. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.057 next year compared to a net loss per share of €0.073 last year.Breakeven Date Change • Jun 11Forecast to breakeven in 2025The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% per year to 2024. The company is expected to make a profit of €2.00m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.공시 • Jun 05Directa Plus Plc, Annual General Meeting, Jun 27, 2024Directa Plus Plc, Annual General Meeting, Jun 27, 2024. Location: 7th floor, 50 broadway, sw1h 0db, london United KingdomNew Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (UK£13.5m market cap, or US$16.8m).공시 • Feb 27Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million.Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million on February 26, 2024. The Consideration is structured as an immediate payment of €0.5 million, which has been paid from Directa's existing cash resources, and a further payment of €1.0 million, which is due prior to March 30, 2024. For the year ended December 31, 2023, Setcar has reported revenues of €7.66 million, EBITDA of €0.35 million and net assets of €2.7 million. The completion of the acquisition is conditional on, inter alia, the payment of total consideration of €1.5 million and the passing of certain resolutions by the shareholders of Setcar at a shareholder meeting expected to be held in April 2024. Neil McDonald and Adam Rae of Cavendish Capital Markets Limited acted as financial advisor to Directa Plus.공시 • Feb 13Directa Plus plc Provides Earnings Guidance for the Year Ended 31 December 2023Directa Plus Plc provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to report revenues of c. €11 million.분석 기사 • Feb 09Take Care Before Jumping Onto Directa Plus Plc (LON:DCTA) Even Though It's 33% CheaperTo the annoyance of some shareholders, Directa Plus Plc ( LON:DCTA ) shares are down a considerable 33% in the last...New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£12.6m market cap, or US$15.8m).분석 기사 • Dec 19Why We're Not Concerned Yet About Directa Plus Plc's (LON:DCTA) 27% Share Price PlungeUnfortunately for some shareholders, the Directa Plus Plc ( LON:DCTA ) share price has dived 27% in the last thirty...New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (UK£19.8m market cap, or US$25.0m).분석 기사 • Oct 14Is Directa Plus (LON:DCTA) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Sep 28First half 2023 earnings released: €0.028 loss per share (vs €0.034 loss in 1H 2022)First half 2023 results: €0.028 loss per share (improved from €0.034 loss in 1H 2022). Revenue: €4.59m (down 17% from 1H 2022). Net loss: €1.85m (loss narrowed 17% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 5.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 2.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£33.0m market cap, or US$40.9m).Breakeven Date Change • Sep 18Forecast to breakeven in 2025The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.80m in 2025. Average annual earnings growth of 85% is required to achieve expected profit on schedule.공시 • Sep 08Directa Plus Plc to Report First Half, 2023 Results on Sep 27, 2023Directa Plus Plc announced that they will report first half, 2023 results on Sep 27, 2023분석 기사 • Aug 22With Directa Plus Plc (LON:DCTA) It Looks Like You'll Get What You Pay ForWhen you see that almost half of the companies in the Chemicals industry in the United Kingdom have price-to-sales...공시 • Jun 29Directa Plus Receives Two New Italian PatentsDirecta Plus has been granted two new Italian patents, the EP patent, which relates to the 'apparatus for treating materials with plasma', and the ET patent, which relates to the 'composition comprising graphene for the treatment of textile articles'. These new grants represent a step forward in Directa Plus' intellectual property strategy and protects the Company's unique production process and the evolution of its graphene technology. Following the grant of the two patents, Directa Plus' IP portfolio now comprises of 22 patent families, with 84 patents granted and 38 patents pending. EP patent: Covers the apparatus for treating materials with plasma, in particular a device comprising a plasma microwave generator, a waveguide, and a microwave system torch, suitable for generating and sustaining atmospheric thermal plasma for treating powder materials. This is key to the Group's IP strategy as plasma technology sits at the core of Directa Plus' unique production process and is what distinguishes the Company from its competitors. Through its plasma technology, Directa Plus generates super-expanded graphite (Grafysorber®) with unique properties and performances in a chemical-free process. The EP patent is the technical evolution of the patent for 'production of nano-structures', and covers all the engineering improvements made to the plasma system to enhance the performance of the technology in terms of yields and the quality of the super expanded graphite obtained. The patent priority date is 19 December 2018. ET Patent: Covers the composition for treating textile articles and is a further evolution of the use of G+ in textiles, expanding the Group's patent coverage in textile applications. It covers a 100% natural and environmentally sustainable printing paste enhanced by graphene's antimicrobial, electrical and thermal conductivity properties. The patent also protects textile articles treated with the composition, including manufactured products for personal health protection. The natural make-up of this composition firmly aligns with Directa Plus' focus on sustainability and environmental protection. The patent priority date is the 4 May 2021.공시 • Jun 09Directa Plus plc Announces the Launch of New Product, GRAPHITODirecta Plus announced the launch of a new product, GRAPHITO, in collaboration with Candiani Denim (Candiani), an international textile producer based in Italy, focused on innovation and sustainability. GRAPHITO is an eco-denim textile and represents a significant advancement in the sustainable fashion industry by addressing denim's environmental impact and extending the lifespan of denim garments. GRAPHITO comprises of Directa Plus' patented technology, Graphene, which enhances a fabric with antimicrobial and thermal properties, along with Candiani Denim's bio-based polymer, Kitotex, which replaces liquid plastic (PVA) in textile production processes, making GRAPHITO denim unique and unrivalled. The enhanced properties of the material will see a significant reduction in water usage, energy consumption and carbon emissions of up to 75% in the garment's wash lifecycle, as the material's antibacterial and antiviral properties allows for up to 10 wear per lifecycle. Graphene's thermoregulating properties also make it a cross-seasonal denim fabric. The launch of GRAPHITO denim marks a significant milestone in the quest for eco-friendly fashion, offering consumers a premier denim choice that combines style, performance, and a reduced environmental footprint. GRAPHITO denim is launching in Candiani Denim's store in Milan, Italy. Candiani was founded in 1934 and has grown to become one of the world's most sustainable denim factories, creating premium fabrics, using eco-friendly techniques. Candiani supplies and partners with some of the world's best known fashion brands, including Hugo Boss, Stella Paul, and Steve Aoki.공시 • May 20Directa Plus Plc, Annual General Meeting, Jun 15, 2023Directa Plus Plc, Annual General Meeting, Jun 15, 2023, at 14:00 Coordinated Universal Time. Location: 7th Floor, 50 Broadway London United KingdomReported Earnings • May 12Full year 2022 earnings released: €0.07 loss per share (vs €0.06 loss in FY 2021)Full year 2022 results: €0.07 loss per share (further deteriorated from €0.06 loss in FY 2021). Revenue: €11.3m (up 31% from FY 2021). Net loss: €4.82m (loss widened 32% from FY 2021). Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Price Target Changed • May 12Price target decreased by 15% to UK£1.78Down from UK£2.10, the current price target is provided by 1 analyst. New target price is 147% above last closing price of UK£0.72. Stock is down 33% over the past year. The company posted a net loss per share of €0.07 last year.분석 기사 • Dec 10Is Directa Plus (LON:DCTA) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • Nov 21Directa Plus plc Announces Directorate ChangeDirecta Plus announce the appointment of Sarah Cope as a Non-executive director. Sarah has over 20 years' experience as an investment banker in London, advising small and mid-sized companies on corporate governance, strategy, amalgamations and disposals, capital markets and regulatory compliance. She has predominantly advised AIM listed companies in the Oil and Gas sector, assisting publicly traded companies to raise finance for their exploration, development and production projects around the world. Following this appointment, Neil Warner has stepped down from the Board. As a consequence, Sarah will be nominated to take over from Neil as the Chair of the Audit Committee.Price Target Changed • Nov 16Price target increased to UK£2.10Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 150% above last closing price of UK£0.84. Stock is down 45% over the past year. The company posted a net loss per share of €0.06 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Oct 17Directa Plus plc Appoints General Wesley K. Clark, as Non-Executive DirectorDirecta Plus Plc announce the appointment of General Wesley K. Clark, (US Army ret.) as a Non-Executive Director. Wesley K. Clark is a businessman, educator, and writer, with wide experience in sectors including energy, oil and gas, biofuels, electric power and batteries and his experience and skill are aligned with the Company's strategic ambitions in the North American market. General Clark, a US national, is Chairman and CEO of Wesley K. Clark & Associates, a strategic consulting firm, Chairman and Founder of Enverra Inc., a licensed investment bank, and Chairman of Energy Security Partners, LLC. In the not-for-profit space, he is a Senior Fellow at UCLA's Burkle Center for International Relations and a Director of the Atlantic Council. A best-selling author, General Clark has written four books and is a frequent contributor to TV and to news media. Wesley Clark retired as a four-star general after 38 years in the United States Army, having served in his last posts as Commander of US Southern Command and then as Commander of US European Command/Supreme Allied Commander, Europe. He graduated first in his class at West Point and completed degrees in Philosophy, Politics and Economics at Oxford University (B.A. and M.A.) as a Rhodes scholar. He also worked with Ambassador Richard Holbrooke in the Dayton Peace Process, where he helped write and negotiate significant portions of the 1995 Dayton Peace Agreement. In his final assignment as Supreme Allied Commander Europe he led NATO forces to victory in Operation Allied Force, a 78-day air campaign, backed by ground invasion planning and a diplomatic process, saving 1.5 million Albanians from ethnic cleansing. His awards include the Presidential Medal of Freedom, Defense Distinguished Service Medal (five awards), Silver Star, Bronze Star, Purple Heart, honorary knighthoods from the British and Dutch governments, and numerous other awards from other governments, including the award of Commander of the Ordre National de la Légion d'honneur. He has also been awarded the Department of State Distinguished Service Award and numerous honorary doctorates. Following this appointment, David Gann has stepped down from the Board.Reported Earnings • Sep 30First half 2022 earnings released: €0.03 loss per share (vs €0.024 loss in 1H 2021)First half 2022 results: €0.03 loss per share (further deteriorated from €0.024 loss in 1H 2021). Revenue: €5.61m (up 42% from 1H 2021). Net loss: €2.23m (loss widened 51% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 8.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Sep 29Forecast to breakeven in 2023The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €200.4k in 2023. Average annual earnings growth of 103% is required to achieve expected profit on schedule.공시 • Sep 02Directa Plus Plc to Report First Half, 2022 Results on Sep 29, 2022Directa Plus Plc announced that they will report first half, 2022 results on Sep 29, 2022공시 • Aug 30Directa Plus Plc Provides US Patent NoticeDirecta Plus announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+® embedded polyurethane membrane, developed explicitly for the textile industry, together with its production method and its applications. The patent, titled "Polyurethane film comprising graphene and preparation process thereof", has apriority date of 5 May 2017. The official grant, expected shortly, will follow on from the completion of the filing process. G+® membranes are highly functional membranes that combine breathability and water protection with thermal and electrical conductivity. They provide superior thermal comfort by enhancing heat retention, due to high infrared absorption, while equalising it as a result of high in-plane thermal conductivity. They are electrically conductive, and the conductivity properties can be adjusted to confer antistatic behaviours for heating. Directa Plus' G+® membranes are non-toxic, non-cytotoxic, and safe against the skin. The membranes are used in apparel markets including the sportswear, workwear, military, luxury and accessories segments. In addition, they are being developed for use in the automotive, filtration and upholstery markets. Following the official grant of the patent, Directa Plus's IP portfolio will comprise 20 patent families with 80 patents granted and 30 patents pending.Major Estimate Revision • Jul 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €14.0m to €14.2m. Forecast EPS reduced from -€0.01 to -€0.04 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 29% next year. Consensus price target of UK£2.53 unchanged from last update. Share price was steady at UK£0.99 over the past week.공시 • Jun 22Directa Plus Plc Grants Italian Filtration PatentDirecta Plus announced that the Company has been granted an Italian patent covering the use of the Company's G+® pristine graphene nanoplatelets applied totextile substrates for high bacterial filtration efficiency media for filtration applications. The priority date for the patent is 25 May 2020. G+® applied to textile substrates provides proven antibacterial and antiviral (including anti-SARS-CoV-2) performance. The target filtration market applications cover both medical and industrial use. Directa Plus started work on air filtration in 2020 with a signature project that successfully supplied face masks with anti-SARS-CoV-2 protection. This work led quickly into exploring industrial filtration applications starting with the automotive and HVAC (heating, ventilation and air conditioning) markets. Directa Plus, as already announced, has partnered with a leading worldwide supplier of non-woven textile materials to develop a suite of new products for automotive and industrial applications based on the antimicrobial properties (antibacterial and antiviral), thermal comfort and electrical conductivity properties of G+® enhanced fabrics. Following the grant of the patent, Directa Plus's IP portfolio comprises 20 patent families with 73 patents granted and 28 patents pending.공시 • Jun 18Directa Plus plc Announces Executive ChangesDirecta Plus announced that Sir Peter Middleton will step down as Chairman following the Meeting, which is in line with his intention to step down announced on the 19 May 2022. Richard Hickinbotham has been appointed interim Chairman. The Board of Directors is committed to an immediate process of consultation to review and refresh the constitution of the Board, in particular to bring additional diversity and expertise to the Company.공시 • May 20Directa Plus Plc, Annual General Meeting, Jun 17, 2022Directa Plus Plc, Annual General Meeting, Jun 17, 2022, at 09:30 Coordinated Universal Time. Location: at 11-12 St. James's Square London United KingdomReported Earnings • May 06Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.06 loss per share (up from €0.069 loss in FY 2020). Revenue: €9.45m (up 47% from FY 2020). Net loss: €3.65m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 42% compared to a 17% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.Price Target Changed • Apr 27Price target increased to UK£2.38Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 98% above last closing price of UK£1.20. Stock is up 4.3% over the past year. The company is forecast to post a net loss per share of €0.049 next year compared to a net loss per share of €0.069 last year.공시 • Apr 04Directa Plus Receives Authorisation from the United States Environment Protection AgencyDirecta Plus announced that it has received authorisation from the United States Environment Protection Agency for the Company's Grafysorber® technology to be used on any oil contamination on US territory. Directa Plus's patented Grafysorber® technology is a graphene-based solution for treating water sludges and emulsions containing hydrocarbons and is at least five times more effective than current technologies - adsorbing more than 100 times its own weight of oil-based pollutants. In addition, Grafysorber® is sustainably produced, non-flammable and reusable, with the adsorbed hydrocarbons recoverable. The approval follows a first presentation of the technology to the California Natural Resource Agency, the highest Californian environmental authority, which suggested that Directa Plus undertook the authorization process with the US Federal Environmental Protection Agency (EPA) to allow the use of Grafysorber® in the United States. After a full review of the information provided by Directa Plus, the US EPA has issued an official authorization letter stating that Grafysorber® fully meets the EPA's legal requirements and can be used at any oil spill on US territory.Board Change • Dec 31High number of new directorsCFO & Director Giorgio Bonfanti was the last director to join the board, commencing their role in 2021.분석 기사 • Nov 10Directa Plus Plc (LON:DCTA) Shares Could Be 31% Below Their Intrinsic Value EstimateToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Directa Plus Plc...Reported Earnings • Oct 01First half 2021 earnings released: €0.024 loss per share (vs €0.038 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €3.95m (up 41% from 1H 2020). Net loss: €1.48m (loss narrowed 36% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 19Is Directa Plus (LON:DCTA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 19Full year 2020 earnings released: €0.07 loss per share (vs €0.068 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: €6.78m (up 158% from FY 2019). Net loss: €4.20m (loss widened 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.공시 • Apr 28Directa Plus plc Announces Positive Advances in Its Research into Printing Graphene-Based Inks Onto TextilesDirecta Plus Plc announced positive advances in its research into printing graphene-based inks onto textiles. Since two years Directa has been working with an International Textile Group to develop new G+ graphene printing technique for the textile market and in April 2021 for the first time a G+ graphene-based ink, which used a specific grade of graphene developed for the purpose, has been digitally jetted. This is a preliminary result but it proves the feasibility of the technology and is a very important milestone for Directa's product development strategy in the textile vertical.Executive Departure • Apr 03Executive Director has left the companyOn the 31st of March, Marco Ferrari's tenure as Executive Director ended after 4.9 years in the role. As of December 2020, Marco personally held 52.55k shares (UK£43k worth at the time). Marco is the only executive to leave the company over the last 12 months.공시 • Mar 18Directa Plus Plc Provides Revenue Guidance for the First Quarter of Fiscal 2021Directa Plus Plc provided revenue guidance for the first quarter of fiscal 2021. The company announced trading in first quarter of 2021 has been strong, with revenues expected to be around €1.8 million, up 20% from the same period in 2020 (€1.5 million).공시 • Mar 10Directa Plus plc Announces Successful Absorption Evaluation TestDirecta Plus announced that it has received another positive test result relating to the potential for absorption of the Company's pristine graphene nanoplatelets powder (Pure G+®) through human skin. This latest in vitro test showed that there is no absorption potential for Pure G+®, taking the total number of positive in vitro test results to eight. The study was carried out by an independent third party and followed the standards of OECD 428 ("In vitro evaluation of the absorption potential of a product throughout reconstructed human epidermis"). The purpose of the test was the evaluation of the skin absorption potential of Pure G+® through an in vitro reconstructed human epidermis. Pure G+ was applied on the tissue surface for six and 24 hours and at the end of the experimental time, a calculation of the quantity of Pure G+® graphene that had penetrated through the epidermis was performed. The acquisition of further successful results from in vitro tests of the Company's hypoallergenic, non-toxic products is vital for their use in textile markets where customers have to be certain of the safety of the apparel they produce and market.분석 기사 • Mar 05Can You Imagine How Jubilant Directa Plus' (LON:DCTA) Shareholders Feel About Its 159% Share Price Gain?It's been a soft week for Directa Plus Plc ( LON:DCTA ) shares, which are down 11%. But in three years the returns have...공시 • Feb 23Directa Plus plc Signs Supply Agreement and A Strategic R&D Agreement with Nextech Batteries IncDirecta Plus Plc announce that the company has signed a supply agreement and a Strategic R&D Agreement with NexTech Batteries Inc. ("NexTech"), a leading company in the field of Lithium Sulphur ("Li-S") batteries based in Nevada, US. These agreements follow on from the Memorandum of Understanding entered into between the two companies and announced on 26 October 2020. The Supply Agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement and governs the provision of a specific grade of G+® pristine graphene nanoplatelets by Directa Plus to NexTech for the production of the active materials of the cathode in NexTech's first generation of Li-S batteries. Under the Supply Agreement, Directa Plus will supply NexTech with 300kg of nanoplatelets in 2021, with quantities for delivery in each subsequent year to be agreed between the parties at the end of each year and subject to the achievement of order quantities related to NexTech's anticipated growth. Directa Plus and NexTech have also agreed a worldwide bilateral exclusivity between the parties in the lithium battery field for the duration of the Supply Agreement. The R&D Agreement, also with a duration of three years, provides for Joint Lab activities with the intention of developing new specific grades of G+® graphene nanoplatelets for a next generation of Li-S batteries. Both parties will dedicate selected scientists from their R&D teams and part of their respective facilities to the enterprise.Is New 90 Day High Low • Feb 04New 90-day high: UK£0.97The company is up 55% from its price of UK£0.63 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.공시 • Jan 22+ 2 more updatesDirecta Plus plc Announces Addition to Decontamination and Recovery ContractDirecta Plus announced that it has had its contract (the "Contract") with OMV Petrom extended and increased. The Contract, initially awarded in July 2019, was for the provision of decontamination and oil recovery services using the Company's proprietary Grafysorber® technology. The initial value of the contract was €150,000 (of which €75,000 was delivered and invoiced in 2020) and this has now been increased to up to €410,000, with the balance of which is expected to be fulfilled by June 2021. The Contract relates to oil recovery from existing high-volume emulsions stored in the OMV Petrom Tank Farms in Romania. The project was paused in 2020 as a result of the pandemic but resumed in November 2020 and this month saw the treatment capacity increased to 2,000 cubic meters of emulsion per month. The extension has been agreed on the basis of the positive results to date of the Grafysorber® technology.Is New 90 Day High Low • Jan 15New 90-day high: UK£0.93The company is up 36% from its price of UK£0.68 on 16 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 23New 90-day high: UK£0.92The company is up 12% from its price of UK£0.82 on 25 August 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 02New 90-day low: UK£0.65The company is down 15% from its price of UK£0.76 on 04 August 2020. The British market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 12New 90-day low: UK£0.69The company is down 4.0% from its price of UK£0.72 on 14 July 2020. The British market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.주주 수익률DCTAGB ChemicalsGB 시장7D-0.7%0.3%0.5%1Y-6.0%9.7%18.0%전체 주주 수익률 보기수익률 대 산업: DCTA은 지난 1년 동안 9.7%의 수익을 기록한 UK Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: DCTA은 지난 1년 동안 18%를 기록한 UK 시장보다 저조한 성과를 냈습니다.주가 변동성Is DCTA's price volatile compared to industry and market?DCTA volatilityDCTA Average Weekly Movement18.9%Chemicals Industry Average Movement8.0%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%안정적인 주가: DCTA의 주가는 지난 3개월 동안 UK 시장보다 변동성이 컸습니다.시간에 따른 변동성: DCTA의 주간 변동성(19%)은 지난 1년 동안 안정적이었지만 UK 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2003180Giulio Cesareowww.directa-plus.comDirecta Plus Plc는 이탈리아, 루마니아 및 전 세계에서 산업 및 상업용 그래핀 기반 제품을 제조 및 판매합니다. 이 회사는 섬유, 환경 및 기타 부문을 통해 운영됩니다. G+라는 브랜드명으로 제품을 제공합니다.더 보기Directa Plus Plc 기초 지표 요약Directa Plus의 순이익과 매출은 시가총액과 어떻게 비교됩니까?DCTA 기초 통계시가총액UK£7.00m순이익 (TTM)-UK£3.74m매출 (TTM)UK£6.21m1.1x주가매출비율(P/S)-1.9x주가수익비율(P/E)DCTA는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표DCTA 손익계산서 (TTM)매출€7.17m매출원가€3.41m총이익€3.76m기타 비용€8.08m순이익-€4.32m최근 보고된 실적Jun 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)-0.041총이익률52.42%순이익률-60.20%부채/자본 비율25.0%DCTA의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 03:57종가2026/05/19 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Directa Plus Plc는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Adam McCarterCavendishJohn-Marc BunceCavendish
Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Nee Wharry Cope was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 29Directa Plus plc Announces Resignation of Wesley Clark as Director with Effective 27 April 2026Directa Plus Plc announced that Wesley Clark has resigned as director of the Company with effective 27 April 2026.
New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.05m market cap, or US$9.49m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
공시 • Feb 28Directa Plus Plc announced that it expects to receive €4 million in fundingDirecta Plus Plc announced a private placement of non-dilutive potential loan for gross proceeds of €4 million from new lender Nant Capital, LLC on February 27, 2026.
공시 • Feb 27+ 1 more updateDirecta Plus plc Announces Giorgio Bonfanti Steps Down from the Board, Effective At the End of MarchDirecta Plus Plc announced that Giorgio Bonfanti, the Company's Chief Financial Officer, has informed the Board of his intention to step down as a director of the Company, to pursue a new business opportunity, and will leave the Group at the end of March. The Board has commenced a recruitment process for a permanent replacement and in the meantime, a UK based finance professional with AIM experience will act as interim CFO.
공시 • Jan 07Directa Plus plc Announces Changes to Its Board, Effective from January 31, 2026Directa Plus Plc announced that Richard Hickinbotham, Non-Executive Chairman, who would have shortly completed his nine-year tenure with the Group, has informed the Board of his intention to take up a full-time executive role and will step down from the Board on 31 January 2026. Giulio Cesareo will assume the role of Interim plc Chairman with effect from that date.
Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Nee Wharry Cope was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 29Directa Plus plc Announces Resignation of Wesley Clark as Director with Effective 27 April 2026Directa Plus Plc announced that Wesley Clark has resigned as director of the Company with effective 27 April 2026.
New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.05m market cap, or US$9.49m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
공시 • Feb 28Directa Plus Plc announced that it expects to receive €4 million in fundingDirecta Plus Plc announced a private placement of non-dilutive potential loan for gross proceeds of €4 million from new lender Nant Capital, LLC on February 27, 2026.
공시 • Feb 27+ 1 more updateDirecta Plus plc Announces Giorgio Bonfanti Steps Down from the Board, Effective At the End of MarchDirecta Plus Plc announced that Giorgio Bonfanti, the Company's Chief Financial Officer, has informed the Board of his intention to step down as a director of the Company, to pursue a new business opportunity, and will leave the Group at the end of March. The Board has commenced a recruitment process for a permanent replacement and in the meantime, a UK based finance professional with AIM experience will act as interim CFO.
공시 • Jan 07Directa Plus plc Announces Changes to Its Board, Effective from January 31, 2026Directa Plus Plc announced that Richard Hickinbotham, Non-Executive Chairman, who would have shortly completed his nine-year tenure with the Group, has informed the Board of his intention to take up a full-time executive role and will step down from the Board on 31 January 2026. Giulio Cesareo will assume the role of Interim plc Chairman with effect from that date.
New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£11.0m market cap, or US$14.8m).
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Non-Executive Director Nee Wharry Cope was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
분석 기사 • Oct 06Health Check: How Prudently Does Directa Plus (LON:DCTA) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 28First half 2025 earnings released: €0.016 loss per share (vs €0.037 loss in 1H 2024)First half 2025 results: €0.016 loss per share (improved from €0.037 loss in 1H 2024). Revenue: €3.90m (up 15% from 1H 2024). Net loss: €1.65m (loss narrowed 33% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
New Risk • Sep 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (UK£10.7m market cap, or US$14.4m).
공시 • Aug 04Directa Plus Plc to Report First Half, 2025 Results on Sep 24, 2025Directa Plus Plc announced that they will report first half, 2025 results on Sep 24, 2025
New Risk • Jun 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 4.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risk Market cap is less than US$100m (UK£12.5m market cap, or US$17.0m).
분석 기사 • Jun 12Is Directa Plus (LON:DCTA) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • Jun 07Directa Plus Plc, Annual General Meeting, Jun 30, 2025Directa Plus Plc, Annual General Meeting, Jun 30, 2025. Location: 7th floor, 50 broadway, sw1h 0db, london United Kingdom
Reported Earnings • Jun 03Full year 2024 earnings released: €0.06 loss per share (vs €0.058 loss in FY 2023)Full year 2024 results: €0.06 loss per share (further deteriorated from €0.058 loss in FY 2023). Revenue: €6.83m (down 35% from FY 2023). Net loss: €5.14m (loss widened 33% from FY 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.90m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
분석 기사 • Mar 27Investors Aren't Entirely Convinced By Directa Plus Plc's (LON:DCTA) RevenuesWith a median price-to-sales (or "P/S") ratio of close to 1.2x in the Chemicals industry in the United Kingdom, you...
New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.74m market cap, or US$8.52m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.27m market cap, or US$7.80m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (7.2% average weekly change).
New Risk • Dec 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.57m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (10% average weekly change).
Major Estimate Revision • Oct 02Consensus revenue estimates decrease by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €17.3m to €7.30m. EPS estimate unchanged from -€0.026 per share at last update. Chemicals industry in the United Kingdom expected to see average net income growth of 44% next year. Consensus price target of UK£1.15 unchanged from last update. Share price fell 28% to UK£0.12 over the past week.
Reported Earnings • Sep 27First half 2024 earnings released: €0.037 loss per share (vs €0.028 loss in 1H 2023)First half 2024 results: €0.037 loss per share (further deteriorated from €0.028 loss in 1H 2023). Revenue: €3.39m (down 26% from 1H 2023). Net loss: €2.47m (loss widened 34% from 1H 2023). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
분석 기사 • Sep 26Investors Give Directa Plus Plc (LON:DCTA) Shares A 39% HidingThe Directa Plus Plc ( LON:DCTA ) share price has fared very poorly over the last month, falling by a substantial 39...
New Risk • Sep 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Market cap is less than US$100m (UK£11.7m market cap, or US$15.6m).
공시 • Sep 13Directa Plus Plc to Report First Half, 2024 Results on Sep 25, 2024Directa Plus Plc announced that they will report first half, 2024 results on Sep 25, 2024
New Risk • Jul 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£21.9m market cap, or US$28.1m).
분석 기사 • Jun 28A Piece Of The Puzzle Missing From Directa Plus Plc's (LON:DCTA) Share PriceThere wouldn't be many who think Directa Plus Plc's ( LON:DCTA ) price-to-sales (or "P/S") ratio of 1.2x is worth a...
Reported Earnings • Jun 27Full year 2023 earnings released: €0.06 loss per share (vs €0.073 loss in FY 2022)Full year 2023 results: €0.06 loss per share (improved from €0.073 loss in FY 2022). Revenue: €10.9m (flat on FY 2022). Net loss: €3.86m (loss narrowed 20% from FY 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Jun 13Price target decreased by 20% to UK£1.28Down from UK£1.59, the current price target is an average from 2 analysts. New target price is 589% above last closing price of UK£0.18. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.057 next year compared to a net loss per share of €0.073 last year.
Breakeven Date Change • Jun 11Forecast to breakeven in 2025The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% per year to 2024. The company is expected to make a profit of €2.00m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
공시 • Jun 05Directa Plus Plc, Annual General Meeting, Jun 27, 2024Directa Plus Plc, Annual General Meeting, Jun 27, 2024. Location: 7th floor, 50 broadway, sw1h 0db, london United Kingdom
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (UK£13.5m market cap, or US$16.8m).
공시 • Feb 27Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million.Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million on February 26, 2024. The Consideration is structured as an immediate payment of €0.5 million, which has been paid from Directa's existing cash resources, and a further payment of €1.0 million, which is due prior to March 30, 2024. For the year ended December 31, 2023, Setcar has reported revenues of €7.66 million, EBITDA of €0.35 million and net assets of €2.7 million. The completion of the acquisition is conditional on, inter alia, the payment of total consideration of €1.5 million and the passing of certain resolutions by the shareholders of Setcar at a shareholder meeting expected to be held in April 2024. Neil McDonald and Adam Rae of Cavendish Capital Markets Limited acted as financial advisor to Directa Plus.
공시 • Feb 13Directa Plus plc Provides Earnings Guidance for the Year Ended 31 December 2023Directa Plus Plc provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to report revenues of c. €11 million.
분석 기사 • Feb 09Take Care Before Jumping Onto Directa Plus Plc (LON:DCTA) Even Though It's 33% CheaperTo the annoyance of some shareholders, Directa Plus Plc ( LON:DCTA ) shares are down a considerable 33% in the last...
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£12.6m market cap, or US$15.8m).
분석 기사 • Dec 19Why We're Not Concerned Yet About Directa Plus Plc's (LON:DCTA) 27% Share Price PlungeUnfortunately for some shareholders, the Directa Plus Plc ( LON:DCTA ) share price has dived 27% in the last thirty...
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (UK£19.8m market cap, or US$25.0m).
분석 기사 • Oct 14Is Directa Plus (LON:DCTA) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Sep 28First half 2023 earnings released: €0.028 loss per share (vs €0.034 loss in 1H 2022)First half 2023 results: €0.028 loss per share (improved from €0.034 loss in 1H 2022). Revenue: €4.59m (down 17% from 1H 2022). Net loss: €1.85m (loss narrowed 17% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 5.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 2.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£33.0m market cap, or US$40.9m).
Breakeven Date Change • Sep 18Forecast to breakeven in 2025The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.80m in 2025. Average annual earnings growth of 85% is required to achieve expected profit on schedule.
공시 • Sep 08Directa Plus Plc to Report First Half, 2023 Results on Sep 27, 2023Directa Plus Plc announced that they will report first half, 2023 results on Sep 27, 2023
분석 기사 • Aug 22With Directa Plus Plc (LON:DCTA) It Looks Like You'll Get What You Pay ForWhen you see that almost half of the companies in the Chemicals industry in the United Kingdom have price-to-sales...
공시 • Jun 29Directa Plus Receives Two New Italian PatentsDirecta Plus has been granted two new Italian patents, the EP patent, which relates to the 'apparatus for treating materials with plasma', and the ET patent, which relates to the 'composition comprising graphene for the treatment of textile articles'. These new grants represent a step forward in Directa Plus' intellectual property strategy and protects the Company's unique production process and the evolution of its graphene technology. Following the grant of the two patents, Directa Plus' IP portfolio now comprises of 22 patent families, with 84 patents granted and 38 patents pending. EP patent: Covers the apparatus for treating materials with plasma, in particular a device comprising a plasma microwave generator, a waveguide, and a microwave system torch, suitable for generating and sustaining atmospheric thermal plasma for treating powder materials. This is key to the Group's IP strategy as plasma technology sits at the core of Directa Plus' unique production process and is what distinguishes the Company from its competitors. Through its plasma technology, Directa Plus generates super-expanded graphite (Grafysorber®) with unique properties and performances in a chemical-free process. The EP patent is the technical evolution of the patent for 'production of nano-structures', and covers all the engineering improvements made to the plasma system to enhance the performance of the technology in terms of yields and the quality of the super expanded graphite obtained. The patent priority date is 19 December 2018. ET Patent: Covers the composition for treating textile articles and is a further evolution of the use of G+ in textiles, expanding the Group's patent coverage in textile applications. It covers a 100% natural and environmentally sustainable printing paste enhanced by graphene's antimicrobial, electrical and thermal conductivity properties. The patent also protects textile articles treated with the composition, including manufactured products for personal health protection. The natural make-up of this composition firmly aligns with Directa Plus' focus on sustainability and environmental protection. The patent priority date is the 4 May 2021.
공시 • Jun 09Directa Plus plc Announces the Launch of New Product, GRAPHITODirecta Plus announced the launch of a new product, GRAPHITO, in collaboration with Candiani Denim (Candiani), an international textile producer based in Italy, focused on innovation and sustainability. GRAPHITO is an eco-denim textile and represents a significant advancement in the sustainable fashion industry by addressing denim's environmental impact and extending the lifespan of denim garments. GRAPHITO comprises of Directa Plus' patented technology, Graphene, which enhances a fabric with antimicrobial and thermal properties, along with Candiani Denim's bio-based polymer, Kitotex, which replaces liquid plastic (PVA) in textile production processes, making GRAPHITO denim unique and unrivalled. The enhanced properties of the material will see a significant reduction in water usage, energy consumption and carbon emissions of up to 75% in the garment's wash lifecycle, as the material's antibacterial and antiviral properties allows for up to 10 wear per lifecycle. Graphene's thermoregulating properties also make it a cross-seasonal denim fabric. The launch of GRAPHITO denim marks a significant milestone in the quest for eco-friendly fashion, offering consumers a premier denim choice that combines style, performance, and a reduced environmental footprint. GRAPHITO denim is launching in Candiani Denim's store in Milan, Italy. Candiani was founded in 1934 and has grown to become one of the world's most sustainable denim factories, creating premium fabrics, using eco-friendly techniques. Candiani supplies and partners with some of the world's best known fashion brands, including Hugo Boss, Stella Paul, and Steve Aoki.
공시 • May 20Directa Plus Plc, Annual General Meeting, Jun 15, 2023Directa Plus Plc, Annual General Meeting, Jun 15, 2023, at 14:00 Coordinated Universal Time. Location: 7th Floor, 50 Broadway London United Kingdom
Reported Earnings • May 12Full year 2022 earnings released: €0.07 loss per share (vs €0.06 loss in FY 2021)Full year 2022 results: €0.07 loss per share (further deteriorated from €0.06 loss in FY 2021). Revenue: €11.3m (up 31% from FY 2021). Net loss: €4.82m (loss widened 32% from FY 2021). Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Price Target Changed • May 12Price target decreased by 15% to UK£1.78Down from UK£2.10, the current price target is provided by 1 analyst. New target price is 147% above last closing price of UK£0.72. Stock is down 33% over the past year. The company posted a net loss per share of €0.07 last year.
분석 기사 • Dec 10Is Directa Plus (LON:DCTA) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • Nov 21Directa Plus plc Announces Directorate ChangeDirecta Plus announce the appointment of Sarah Cope as a Non-executive director. Sarah has over 20 years' experience as an investment banker in London, advising small and mid-sized companies on corporate governance, strategy, amalgamations and disposals, capital markets and regulatory compliance. She has predominantly advised AIM listed companies in the Oil and Gas sector, assisting publicly traded companies to raise finance for their exploration, development and production projects around the world. Following this appointment, Neil Warner has stepped down from the Board. As a consequence, Sarah will be nominated to take over from Neil as the Chair of the Audit Committee.
Price Target Changed • Nov 16Price target increased to UK£2.10Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 150% above last closing price of UK£0.84. Stock is down 45% over the past year. The company posted a net loss per share of €0.06 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Oct 17Directa Plus plc Appoints General Wesley K. Clark, as Non-Executive DirectorDirecta Plus Plc announce the appointment of General Wesley K. Clark, (US Army ret.) as a Non-Executive Director. Wesley K. Clark is a businessman, educator, and writer, with wide experience in sectors including energy, oil and gas, biofuels, electric power and batteries and his experience and skill are aligned with the Company's strategic ambitions in the North American market. General Clark, a US national, is Chairman and CEO of Wesley K. Clark & Associates, a strategic consulting firm, Chairman and Founder of Enverra Inc., a licensed investment bank, and Chairman of Energy Security Partners, LLC. In the not-for-profit space, he is a Senior Fellow at UCLA's Burkle Center for International Relations and a Director of the Atlantic Council. A best-selling author, General Clark has written four books and is a frequent contributor to TV and to news media. Wesley Clark retired as a four-star general after 38 years in the United States Army, having served in his last posts as Commander of US Southern Command and then as Commander of US European Command/Supreme Allied Commander, Europe. He graduated first in his class at West Point and completed degrees in Philosophy, Politics and Economics at Oxford University (B.A. and M.A.) as a Rhodes scholar. He also worked with Ambassador Richard Holbrooke in the Dayton Peace Process, where he helped write and negotiate significant portions of the 1995 Dayton Peace Agreement. In his final assignment as Supreme Allied Commander Europe he led NATO forces to victory in Operation Allied Force, a 78-day air campaign, backed by ground invasion planning and a diplomatic process, saving 1.5 million Albanians from ethnic cleansing. His awards include the Presidential Medal of Freedom, Defense Distinguished Service Medal (five awards), Silver Star, Bronze Star, Purple Heart, honorary knighthoods from the British and Dutch governments, and numerous other awards from other governments, including the award of Commander of the Ordre National de la Légion d'honneur. He has also been awarded the Department of State Distinguished Service Award and numerous honorary doctorates. Following this appointment, David Gann has stepped down from the Board.
Reported Earnings • Sep 30First half 2022 earnings released: €0.03 loss per share (vs €0.024 loss in 1H 2021)First half 2022 results: €0.03 loss per share (further deteriorated from €0.024 loss in 1H 2021). Revenue: €5.61m (up 42% from 1H 2021). Net loss: €2.23m (loss widened 51% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 8.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Sep 29Forecast to breakeven in 2023The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €200.4k in 2023. Average annual earnings growth of 103% is required to achieve expected profit on schedule.
공시 • Sep 02Directa Plus Plc to Report First Half, 2022 Results on Sep 29, 2022Directa Plus Plc announced that they will report first half, 2022 results on Sep 29, 2022
공시 • Aug 30Directa Plus Plc Provides US Patent NoticeDirecta Plus announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+® embedded polyurethane membrane, developed explicitly for the textile industry, together with its production method and its applications. The patent, titled "Polyurethane film comprising graphene and preparation process thereof", has apriority date of 5 May 2017. The official grant, expected shortly, will follow on from the completion of the filing process. G+® membranes are highly functional membranes that combine breathability and water protection with thermal and electrical conductivity. They provide superior thermal comfort by enhancing heat retention, due to high infrared absorption, while equalising it as a result of high in-plane thermal conductivity. They are electrically conductive, and the conductivity properties can be adjusted to confer antistatic behaviours for heating. Directa Plus' G+® membranes are non-toxic, non-cytotoxic, and safe against the skin. The membranes are used in apparel markets including the sportswear, workwear, military, luxury and accessories segments. In addition, they are being developed for use in the automotive, filtration and upholstery markets. Following the official grant of the patent, Directa Plus's IP portfolio will comprise 20 patent families with 80 patents granted and 30 patents pending.
Major Estimate Revision • Jul 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €14.0m to €14.2m. Forecast EPS reduced from -€0.01 to -€0.04 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 29% next year. Consensus price target of UK£2.53 unchanged from last update. Share price was steady at UK£0.99 over the past week.
공시 • Jun 22Directa Plus Plc Grants Italian Filtration PatentDirecta Plus announced that the Company has been granted an Italian patent covering the use of the Company's G+® pristine graphene nanoplatelets applied totextile substrates for high bacterial filtration efficiency media for filtration applications. The priority date for the patent is 25 May 2020. G+® applied to textile substrates provides proven antibacterial and antiviral (including anti-SARS-CoV-2) performance. The target filtration market applications cover both medical and industrial use. Directa Plus started work on air filtration in 2020 with a signature project that successfully supplied face masks with anti-SARS-CoV-2 protection. This work led quickly into exploring industrial filtration applications starting with the automotive and HVAC (heating, ventilation and air conditioning) markets. Directa Plus, as already announced, has partnered with a leading worldwide supplier of non-woven textile materials to develop a suite of new products for automotive and industrial applications based on the antimicrobial properties (antibacterial and antiviral), thermal comfort and electrical conductivity properties of G+® enhanced fabrics. Following the grant of the patent, Directa Plus's IP portfolio comprises 20 patent families with 73 patents granted and 28 patents pending.
공시 • Jun 18Directa Plus plc Announces Executive ChangesDirecta Plus announced that Sir Peter Middleton will step down as Chairman following the Meeting, which is in line with his intention to step down announced on the 19 May 2022. Richard Hickinbotham has been appointed interim Chairman. The Board of Directors is committed to an immediate process of consultation to review and refresh the constitution of the Board, in particular to bring additional diversity and expertise to the Company.
공시 • May 20Directa Plus Plc, Annual General Meeting, Jun 17, 2022Directa Plus Plc, Annual General Meeting, Jun 17, 2022, at 09:30 Coordinated Universal Time. Location: at 11-12 St. James's Square London United Kingdom
Reported Earnings • May 06Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.06 loss per share (up from €0.069 loss in FY 2020). Revenue: €9.45m (up 47% from FY 2020). Net loss: €3.65m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 42% compared to a 17% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.
Price Target Changed • Apr 27Price target increased to UK£2.38Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 98% above last closing price of UK£1.20. Stock is up 4.3% over the past year. The company is forecast to post a net loss per share of €0.049 next year compared to a net loss per share of €0.069 last year.
공시 • Apr 04Directa Plus Receives Authorisation from the United States Environment Protection AgencyDirecta Plus announced that it has received authorisation from the United States Environment Protection Agency for the Company's Grafysorber® technology to be used on any oil contamination on US territory. Directa Plus's patented Grafysorber® technology is a graphene-based solution for treating water sludges and emulsions containing hydrocarbons and is at least five times more effective than current technologies - adsorbing more than 100 times its own weight of oil-based pollutants. In addition, Grafysorber® is sustainably produced, non-flammable and reusable, with the adsorbed hydrocarbons recoverable. The approval follows a first presentation of the technology to the California Natural Resource Agency, the highest Californian environmental authority, which suggested that Directa Plus undertook the authorization process with the US Federal Environmental Protection Agency (EPA) to allow the use of Grafysorber® in the United States. After a full review of the information provided by Directa Plus, the US EPA has issued an official authorization letter stating that Grafysorber® fully meets the EPA's legal requirements and can be used at any oil spill on US territory.
Board Change • Dec 31High number of new directorsCFO & Director Giorgio Bonfanti was the last director to join the board, commencing their role in 2021.
분석 기사 • Nov 10Directa Plus Plc (LON:DCTA) Shares Could Be 31% Below Their Intrinsic Value EstimateToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Directa Plus Plc...
Reported Earnings • Oct 01First half 2021 earnings released: €0.024 loss per share (vs €0.038 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €3.95m (up 41% from 1H 2020). Net loss: €1.48m (loss narrowed 36% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 19Is Directa Plus (LON:DCTA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 19Full year 2020 earnings released: €0.07 loss per share (vs €0.068 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: €6.78m (up 158% from FY 2019). Net loss: €4.20m (loss widened 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Apr 28Directa Plus plc Announces Positive Advances in Its Research into Printing Graphene-Based Inks Onto TextilesDirecta Plus Plc announced positive advances in its research into printing graphene-based inks onto textiles. Since two years Directa has been working with an International Textile Group to develop new G+ graphene printing technique for the textile market and in April 2021 for the first time a G+ graphene-based ink, which used a specific grade of graphene developed for the purpose, has been digitally jetted. This is a preliminary result but it proves the feasibility of the technology and is a very important milestone for Directa's product development strategy in the textile vertical.
Executive Departure • Apr 03Executive Director has left the companyOn the 31st of March, Marco Ferrari's tenure as Executive Director ended after 4.9 years in the role. As of December 2020, Marco personally held 52.55k shares (UK£43k worth at the time). Marco is the only executive to leave the company over the last 12 months.
공시 • Mar 18Directa Plus Plc Provides Revenue Guidance for the First Quarter of Fiscal 2021Directa Plus Plc provided revenue guidance for the first quarter of fiscal 2021. The company announced trading in first quarter of 2021 has been strong, with revenues expected to be around €1.8 million, up 20% from the same period in 2020 (€1.5 million).
공시 • Mar 10Directa Plus plc Announces Successful Absorption Evaluation TestDirecta Plus announced that it has received another positive test result relating to the potential for absorption of the Company's pristine graphene nanoplatelets powder (Pure G+®) through human skin. This latest in vitro test showed that there is no absorption potential for Pure G+®, taking the total number of positive in vitro test results to eight. The study was carried out by an independent third party and followed the standards of OECD 428 ("In vitro evaluation of the absorption potential of a product throughout reconstructed human epidermis"). The purpose of the test was the evaluation of the skin absorption potential of Pure G+® through an in vitro reconstructed human epidermis. Pure G+ was applied on the tissue surface for six and 24 hours and at the end of the experimental time, a calculation of the quantity of Pure G+® graphene that had penetrated through the epidermis was performed. The acquisition of further successful results from in vitro tests of the Company's hypoallergenic, non-toxic products is vital for their use in textile markets where customers have to be certain of the safety of the apparel they produce and market.
분석 기사 • Mar 05Can You Imagine How Jubilant Directa Plus' (LON:DCTA) Shareholders Feel About Its 159% Share Price Gain?It's been a soft week for Directa Plus Plc ( LON:DCTA ) shares, which are down 11%. But in three years the returns have...
공시 • Feb 23Directa Plus plc Signs Supply Agreement and A Strategic R&D Agreement with Nextech Batteries IncDirecta Plus Plc announce that the company has signed a supply agreement and a Strategic R&D Agreement with NexTech Batteries Inc. ("NexTech"), a leading company in the field of Lithium Sulphur ("Li-S") batteries based in Nevada, US. These agreements follow on from the Memorandum of Understanding entered into between the two companies and announced on 26 October 2020. The Supply Agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement and governs the provision of a specific grade of G+® pristine graphene nanoplatelets by Directa Plus to NexTech for the production of the active materials of the cathode in NexTech's first generation of Li-S batteries. Under the Supply Agreement, Directa Plus will supply NexTech with 300kg of nanoplatelets in 2021, with quantities for delivery in each subsequent year to be agreed between the parties at the end of each year and subject to the achievement of order quantities related to NexTech's anticipated growth. Directa Plus and NexTech have also agreed a worldwide bilateral exclusivity between the parties in the lithium battery field for the duration of the Supply Agreement. The R&D Agreement, also with a duration of three years, provides for Joint Lab activities with the intention of developing new specific grades of G+® graphene nanoplatelets for a next generation of Li-S batteries. Both parties will dedicate selected scientists from their R&D teams and part of their respective facilities to the enterprise.
Is New 90 Day High Low • Feb 04New 90-day high: UK£0.97The company is up 55% from its price of UK£0.63 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.
공시 • Jan 22+ 2 more updatesDirecta Plus plc Announces Addition to Decontamination and Recovery ContractDirecta Plus announced that it has had its contract (the "Contract") with OMV Petrom extended and increased. The Contract, initially awarded in July 2019, was for the provision of decontamination and oil recovery services using the Company's proprietary Grafysorber® technology. The initial value of the contract was €150,000 (of which €75,000 was delivered and invoiced in 2020) and this has now been increased to up to €410,000, with the balance of which is expected to be fulfilled by June 2021. The Contract relates to oil recovery from existing high-volume emulsions stored in the OMV Petrom Tank Farms in Romania. The project was paused in 2020 as a result of the pandemic but resumed in November 2020 and this month saw the treatment capacity increased to 2,000 cubic meters of emulsion per month. The extension has been agreed on the basis of the positive results to date of the Grafysorber® technology.
Is New 90 Day High Low • Jan 15New 90-day high: UK£0.93The company is up 36% from its price of UK£0.68 on 16 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 23New 90-day high: UK£0.92The company is up 12% from its price of UK£0.82 on 25 August 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 02New 90-day low: UK£0.65The company is down 15% from its price of UK£0.76 on 04 August 2020. The British market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 12New 90-day low: UK£0.69The company is down 4.0% from its price of UK£0.72 on 14 July 2020. The British market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
